A specialty subsidiary of Innoviva and the Global Antibiotic Research & Development Partnership conducted the research into the pathogen deemed a priority by the World Health Organization.
GARDP called the clinical trial “pivotal” and “unprecedented” as antimicrobial resistance rises.
“Study investigators found that oral zoliflodacin demonstrated statistical non-inferiority of microbiological cure at the urogenital site when compared to treatment with intramuscular injection of ceftriaxone and oral azithromycin, a current global standard of care regimen,” the organization said in a news release.
If zoliflodacin is approved, it will be the first new gonorrhea antibiotic in decades.
Gonorrhea is the third-most common sexually transmitted infection, and it affects 82 million people per year, according to GARDP.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
